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HASIL KLINIKAL TERAPI INDUKSI SELEPAS PENAMBAHAN DOS 
TINGGI METHOTREXATE DAN CYTARABINE KEPADA REGIMEN 
STANDARD DALAM KALANGAN PESAKIT BARU DIFFUSED LARGE B-
CELL LYMPHOMA: ANALISIS RETROSPEKTIF 
 
ABSTRAK 
 
Diffused large B-cell lymphoma (DLBCL) merupakan penyakit yang 
heterogenus di mana hasil rawatan bergantung kepada ciri-ciri klinikal dan biologikal 
penyakit. Walau bagaimanapun, rawatan induksi optimum untuk pesakit DLBCL yang 
berisiko tinggi masih tidak jelas dan memerlukan kajian klinikal yang lebih untuk 
memahami dan menilai kaedah alternatif. Kajian ini bertujuan untuk menilai kadar 
respon dan remission jangka masa panjang hasil rawatan induksi selepas penambahan 
dos tinggi methotrexate dan cytarabine kepada regimen RCHOP dalam kalangan pesakit 
yang didiagnos dengan DLBCL. Sebanyak 62 pesakit DLBCL yang didiagnos antara 
bulan Januari 2011 sehingga Disember 2014 telah dianalisa secara retrospektif. Purata 
umur sewaktu diagnosis untuk pesakit DLBCL adalah 50 ± 13.4 tahun (julat 18 – 77 
tahun). Seramai 38 pesakit menerima rawatan RCHOP/CHOP bersama methotrexate 
atau cytarabine atau kedua-duanya (RCHOP/CHOP+MA/M/A) sementara 24 pesakit 
hanya menerima RCHOP/CHOP regimen. Kaedah Kaplan-Meier dan ujian log-rank 
telah digunakan untuk menganalisis faktor-faktor bagi analisis univariate. Kadar 
complete remission (CR) adalah lebih tinggi bagi pesakit yang menerima rawatan 
RCHOP/CHOP+MA/M/A (65.8%) berbanding dengan pesakit yang menerima rawatan 
xii 
 
RCHOP/CHOP (37.5%). Terdapat perbezaan yang signifikan dari segi overall survival 
(OS) bagi pesakit yang menunjukkan simptom B berbanding dengan pesakit yang tidak 
menunjukkan simptom B (p = 0.02). Berdasarkan kepada respon awal rawatan, pesakit 
yang mencapai complete remission (CR) didapati memaparkan peningkatkan OS yang 
signifikan (p < 0.0001).  Antara 62 pesakit DLBCL yang menerima rawatan kemoterapi 
≥ 4 kitaran, 2 pesakit (0.5%) meninggal dunia disebabkan komplikasi rawatan (TRM). 
Dalam kajian ini, median overall survival (OS) dan  median progression free survival 
(PFS) masih belum dicapai. Median jangkamasa pemonitoran pesakit (follow-up) adalah 
20 bulan (julat 2-43 months). OS pesakit untuk 2 tahun adalah sebanyak 74% dengan 2 
tahun PFS mencecah 71%. Kadar OS dan PFS bagi 38 pesakit yang menerima rawatan 
RCHOP/CHOP+MA/M/A menunujukkan perbezaan yang ketara berbanding dengan 
kumpulan pesakit yang menerima rawatan RCHOP/CHOP (n = 24) dengan nilai p = 
0.03 and p = 0.04, masing-masing. Selain itu, kumpulan perempuan yang terlibat dalam 
kajian ini menunjukkan pola yang lebih baik dari segi hasil klinikal. Secara 
kesimpulannya, penambahan methotrexate dan cytarabine kepada regimen 
RCHOP/CHOP mendatangkan manfaat dari segi 2 tahun OS dan PFS untuk pesakit 
DLBCL serta mengukuhkan lagi data kajian dari negara lain. 
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CLINICAL OUTCOMES OF INDUCTION THERAPY WITH ADDITION OF 
HIGH DOSE METHOTREXATE AND CYTARABINE TO EXISTING 
STANDARD TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED 
DIFFUSED LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY 
 
ABSTRACT  
 
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous group of diseases 
with various outcomes depending on the clinical and biological features. Optimal 
induction therapy for high-risk DLBCL is still unclear, and clinical trials are needed to 
evaluate alternative approaches. This study aimed to evaluate the response rates and 
long term remission of induction therapy with addition of high dose methotrexate and 
cytarabine onto RCHOP for patients diagnosed with DLBCL. 62 DLBCL patients 
diagnosed between January 2011 to December 2014 were retrospectively analyzed. 
Mean age at diagnosis for enrolled patients was 50 ± 13.4 years (range 18 – 77 years). A 
total of 38 patients received RCHOP/CHOP plus methotrexate or cytarabine or both 
(RCHOP/CHOP+MA/M/A) while 24 patients received only RCHOP/CHOP regimen. 
Kaplan-Meier method and log-rank test were used to analyze factors for univariate 
analysis. The complete remission (CR) rate was higher in the RCHOP/CHOP+MA/M/A 
arm (65.8%) compared to the RCHOP/CHOP arm (37.5%). There was a significant 
difference in overall survival (OS) comparing patients manifested with B symptoms and 
patients without B symptoms (p = 0.02). With respect to the initial response of frontline 
therapy, patients who achieved a complete remission (CR) was associated with 
xiv 
 
significantly improved OS (p < 0.0001).  Among 62 DLBCL patients who received ≥ 4 
cycles chemotherapy, 2 (0.5%) experienced treatment-related mortality (TRM). The 
median overall survival (OS) and median progression free survival (PFS) are not 
reached. Median duration of follow-up was 20 months (range 2-43 months). The 2-year 
OS was 74% with 2-year PFS 71%. Overall survival and progression free survival rates 
of 38 patients received RCHOP/CHOP+MA/M/A showed significantly better compare 
to RCHOP/CHOP group (n = 24) with p = 0.03 and p = 0.04, respectively. Besides, 
there is a trend of  better outcome in female cohort. In conclusion, addition of 
methotrexate and cytarabine onto RCHOP/CHOP regimen resulted in improved 2-year 
OS and PFS of DLBCL patients which confirms the results of previous published study 
in other countries. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Introduction 
 
The most common subtype of non-Hodgkin lymphoma (NHL) is the Diffuse large B 
cell lymphoma (DLBCL) which accounting for approximately one third of all newly 
diagnosed lymphoid malignancy case (Martelli et al., 2013, Sehn and Gascoyne, 2014). 
According to the Malaysia National Cancer Registry Report 2007-2011, lymphoma 
cases accounted for 4.3% of all malignancy incidence reported (National Cancer 
Registry, 2011). Besides, the Melaka Cancer Registry 2015 indicated that the 
prevalence of lymphoma cases is 10: 100,000 population and DLBCL is 5:100,000 
(Sabtu, 2015). This group of disease is derived from large neoplastic B cells and 
clinically manifest aggressive presentation (Savage, 2006). Based on the clinical signs 
and symptoms and morphology characteristics, variants and subtypes of DLBCL have 
been identified in the World Health Organization (WHO) classification and Real 
European-American Lymphoma (REAL) (Harris et al., 1994, Swerdlow et al., 2008). 
Even though morphological, biological and clinical studies are able to differentiate 
DLBCL into distinct disease entities, there is no clear description and accepted criteria 
for sub-classification in many cases, which still remain them biologically and clinically 
heterogenous. By and large, these are called as DLBCL, not otherwise specified (NOS) 
(Swerdlow et al., 2008).   
 
 
2 
 
As the age increases; reaching a peak in the late 70’s years old and above, the  
incidence of DLBCL increases as well. Conversely, other types of aggressive NHL for 
example primary mediastinal lymphoma and Burkitt lymphoma, occur at a lower 
median age (Peyrade et al., 2011).  Differences should identified between cases arising 
de novo (referred as primary) and those categorized under progression or transformation 
(referred to secondary) of a less aggressive lymphoma, which include follicular 
lymphoma, marginal zone lymphoma, nodal lymphocyte predominant Hodgkin 
lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma, as most of 
the causes of DLBCL remain unknown.  
 
Factors such as exposure to agent that produces peculiar molecular as well as 
acquired immunodeficiency and congenital states may be predisposing to the disease 
(Hartge P, 2004). Study done by De Roos and colleagues shown that risk of NHL 
increases with the use of several pesticides (De Roos et al., 2003). Drugs used in 
treatment of cancer such as alkylating agents significantly increases the occurrence of 
lymphomas as secondary tumour when used together with ionizing radiation, 
particularly when high volumes of bone marrow or spleen are irradiated (Martelli et al., 
2013). More incidence of diffuse aggressive lymphomas which involved the brain were 
seen in patients taking immunosuppressive drugs, especially after organ transplants 
(Swerdlow et al., 2008). In fact, DLBCL were also found in patients with inherited 
immunologic deficiency diseases, and in families of patients with immunologic 
disorders (Vianna, 1977). 
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Over the last decade, relationships between DLBCL and viruses have become a 
debatable issue. There are few studies reported that aggressive lymphomas were 
associated with hepatitis-C virus (HCV) infection (De Vita et al., 1997, Ascoli et al., 
1998). Additionally, there are a few DLBCL cases reported of EBV-positive while 
patients receiving Alemtuzumab treatment with no prior history of haematological 
malignancy (Abruzzo et al., 2002, Ghobrial IM et al., 2003, Roch et al., 2008, Sohani et 
al., 2010).  The rise of several types of lymphoma has been linked with human 
immunodeficiency virus (HIV) infection as well (Diebold et al., 1997). Normally these 
arises in an early phase of AIDS evolution, which usually were quite aggressive and 
diffused tumours. Nevertheless, the emergence of highly active antiretroviral therapy 
(HAART) treatment has significantly improved and reduced the number of lymphoma 
among HIV positive patients. Besides, the tolerability of chemotherapy also increased 
among the HIV positive patients (Antinori et al., 2001, Ratner et al., 2001, Hoffmann et 
al., 2003, Rossi et al., 2010). 
 
 DLBCL is diagnose with a biopsy examination of affected tissue preferable 
excisional biopsy to make a proper diagnosis. Incisional biopsy or core needle biopsy is 
permitted only in case when excision is not possible (Andersson et al., 1992). 
Evaluation before treatment and staging are the next critical step once the diagnosis 
established. Ann Arbor staging system with Cotswolds modification is the standard 
staging used to stratify DLBCL (Carbone et al., 1971, Lister et al., 1989). Developed in 
1971, Ann Arbor staging system principally based upon the use of staging laparotomy 
and lymphangiogram. It has a four stages; ranging from stage I to stage IV (Carbone et 
al., 1971).   
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However, this has been replaced with a bone marrow trephine biopsy and a CT 
scan. Subsequently in year 2014, further revisions to clarify the role of positron 
emission tomography (PET) and improvised extranodal involvement definition were 
suggested in Lugano classification (Barrington et al., 2014, Cheson et al., 2014). Cases 
of NHL are usually categorized as early stage disease (stage I to II) or advanced stage 
disease (stage III to IV). Further stratification into favorable and unfavorable subsets 
were done for patients with early stage NHL.  
 
Prognostic factor for DLBCL can be divided into four, mainly those related 
primarily to the patient clinical characteristic (age and performance status), those related 
to aggressiveness parameters (β2-microglobulin level and serum LDH level), those 
related to therapeutic option and those related to tumour or disease itself (stage, 
proliferating, extranodal involvement and tumour burden). Presence of the lymphoma in 
the extranodal sites, for examples, brain (Ferreri, 2011) and testis (Zucca et al., 2003) 
need special strategies and it usually associated with poor prognosis. Achieving a good 
response rate post induction treatment is pivotal and able to predict the treatment 
outcome.   
 
Later, in regard to more than 4000 patients’ clinical factors, the International 
Prognostic Index (IPI) and age-adjusted International Prognostic Index (aaIPI) was 
established and used as an outcomes predictors (Project, 1993). In fact, it has been 
proven to be better in term of predicting survival outcome compared to the Ann Arbor 
classification. In the clinical practice especially stratifying patients, parameters such as 
aaIPI, which involves LDH level, patient’s performance status and disease stage, are  
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frequently used. During post-rituximab era, an updated version has been created (R-IPI) 
(Sehn et al., 2007). Although robustness of IPI has been reported in different series of  
DLBCL, it still represents the only benchmark to prognosticate DLBCL, even in the 
rituximab era (Ziepert et al., 2010). 
 
There are a vast number of biological parameters which have been verified as 
factors to predict DLBCL prognosis, creating a research field for understanding the 
disease in depth as well as designing new therapeutic options for better survival. In fact, 
biological heterogeneity in DLBCL can be categorized into two distinct groups based 
on their postulated normal lymphoid cell counterpart; activated B-cell like (ABC) and 
germinal-centre like (GC) DLBCL (Lenz  et al., 2008). The GC DLBCL shown 
excellent treatment outcome with standard R-CHOP therapy, whereas the ABC DLBCL 
is associated with poorer outcome. Hernandez and colleagues reported that the use of 
lenalidomide in salvage therapy is associated with a significant higher response rate in 
ABC-DLBCL as compared to GCB-cell-DLBCL (Hernandez-Ilizaliturri et al., 2011). 
This shown that more promising studies are needed particularly focusing on gene 
expression profiling (GEP) to be practise in the clinical setting.  
 
Despite being an aggressive disease, DLBCL can be potentially curable 
malignancies either with combine modality therapy or chemotherapy alone (Martelli et 
al., 2013). The patients with limited disease seem to have better cure rate with 80-85% 
of 5-year progression free survival (PFS) as compared to the advanced disease or 
symptomatic disease, which is 50% of 5-year PFS (Project, 1993). 
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Individual IPI score and age have an influence on the option for first line 
treatment (induction) for DLBCL patients. The CHOP-21 regimen (combination of 
cyclophosphamide 750 mg/m2, doxorubicin [Adriamycin] 50 mg/m2, vincristine 
[Oncovin] 1.4 mg/m2 [to a maximum of 2 mg] given on day 1 and tablet prednisolone 
60 mg/m2 daily from Day 1- Day 5 plus Rituximab) remain the standard treatment for  
patient with DLBCL. This combination of chemotherapy has made a significant 
breakthrough transforming the fatality of patient to often curable disease.  Even though 
outcome of CHOP-14 treatment shown to be better than CHOP-21 in elderly patients (> 
60 years), incorporating rituximab to CHOP (R-CHOP) in either 14- or 21- day 
intervals shown comparable efficacy. In fact, patients received R-CHOP-14 shown to 
have higher toxicities level (Coiffier  et al., 2002, Pfreundschuh et al., 2006b, 
Cunningham et al., 2011). Nevertheless, the clinical outcome still remains poor when 
treating the high-risk DLBCL (IPI score ≥ 3), with an overall survival (OS) rate of 55% 
a 4-year progression-free survival (PFS) rate of 53% (Sehn et al., 2007). 
 
In order to overcome these poor results among young patients with high risk 
features, up-front stem cell transplant was suggested as consolidation after R-CHOP. 
However, up-front consolidation needs transplant specific procedures and it has many 
associated toxicities. Besides, its actual benefits remain controversial (Stiff et al., 2011).  
A higher intensity novel regimen consisting of rituximab plus hyperfractionated 
cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with 
rituximab, high dose methotrexate and cytarabine (R-HCVAD/R-MA) has a significant 
positive result in mantle cell lymphoma (Romaguera et al., 2005, Bernstein et al., 2013), 
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acute lymphoblastic lymphoma (Thomas et al., 2006, Thomas et al., 2010), and Burkitt 
lymphoma (Thomas et al., 2006). Additionally, a retrospective analysis done by Fayad 
shown that 27 consecutive treated DLBCL patients age ≤ 60 years old in MD Anderson 
Cancer Centre had a 95% complete response rate and a 3-year PFS rate of 86% (Fayad 
et al., 2007). 
 
1.2 Rationale for this study 
 
Currently, optimal induction chemotherapy regimen for high risk DLBCL is remain 
questionable, and more studies are necessary to assess alternative approaches other than 
R-CHOP. Studies of different intensive chemotherapy regimen in the US and UK have 
positive impact on overall survival rate. However, there is no study on alternative 
induction chemotherapy conducted in Malaysia and R-CHOP21 regimen remains 
standard despite poor outcome in certain high risks patients. In addition, most of the 
studies conducted in overseas were not representative of Asian population. They can 
only act as a guide and might leads to variations in the responses in different population 
and ethnicity. In fact, study shown that there are inter-ethnic differences in drugs effects 
or their influence by ethnic-specific gene variants. Therefore, is crucial to evaluate the 
effect of alternative induction chemotherapy focusing on high risk DLBCL.  
 
The aim of this study was to evaluate the clinical outcomes of induction therapy 
with addition of high dose methotrexate and cytarabine onto RCHOP21 for patients 
diagnosed with DLBCL, in terms of response rates and long-term remission. Besides, 
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this investigation will provide insight to the field of haematology in Malaysia, through 
providing recommendations to improve the standard of care for DLBCL patients.    
 
1.3 Objectives of this Study 
1.3.1 Primary Objective 
 
To evaluate the complete response rate of induction therapy with addition of high-dose 
Methotrexate and/or Cytarabine onto standard R-CHOP/CHOP (R-
CHOP/CHOP+MA/M/A regimen) as compare to standard R-CHOP/CHOP regimen for 
patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) in 
haematology ward, Hospital Melaka, Malaysia.  
 
1.3.2 Secondary Objectives 
 
1) To assess the response rate (complete response, partial response, stable disease 
or disease progression) at mid-cycle and end of treatment among patients who 
newly diagnosed with DLBCL treated with standard R-CHOP/CHOP alone as 
compared to R-CHOP/CHOP+MA/M/A regimen. 
2) To explore the treatment related mortality among patients who newly diagnosed 
with DLBCL treated with standard R-CHOP/CHOP alone or R-
CHOP/CHOP+MA/M/A regimen. 
3) To assess the overall survival (OS) and progression free survival (PFS) rate 
among patients who newly diagnosed with DLBCL treated with standard R-
CHOP/CHOP alone as compared to R-CHOP/CHOP+MA/M/A regimen. 
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4) To evaluate correlation between age, gender, Ann Arbor staging, B symptoms, 
bulky disease and nodal involvement with treatment related mortality among 
patients who newly diagnosed with DLBCL treated with standard R-
CHOP/CHOP as compared to R-CHOP/CHOP+MA/M/A regimen. 
5) To identify the prognostic factors contributing to the effectiveness of treatment 
for patients who newly diagnosed with DLBCL.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Diffuse large B-cell lymphoma 
2.1.1 Definition and prevalence 
 
Among all the lymphoid malignancy diagnosed in adults, diffuse large B-cell 
lymphoma or known as ‘DLBCL’ is the most common diagnosis. It is estimated that the 
incidence of Non-Hodgkin’s Lymphoma (NHL) has reached be 15-20 cases/100,000 
per year in US (Seer, 2015). Besides, data from WHO Classification of Tumour of 
Haematopoietic and Lymphoid Tissues fourth edition (Swerdlow et al., 2008) and 
International NHL study group (Armitage, 1997) indicated that DLBCL stands about 
one-third of all NHL in western countries and B-cell tumours reported globally. This 
figure maybe increasing as most of the DLBCL cases falls between sixty and seventy of 
age. The other types of aggressive lymphoma usually occur at lower median age, as for 
instance primary mediastinal lymphoma and Burkitt lymphoma . DLBCL contains 
highly proliferating large cells with basophilic cytoplasm, vesicular nuclei and 
prominent nucleoli. Based on 2008 WHO Classification, DLBCLs subdivided into 
molecular and immunophenotypic subgroups, morphological variants, as well as 
distinct disease entities (Swerdlow et al., 2008).  
 
 Currently, there are some cases of DLBCL which still remain undefined. 
Due to biologically heterogenous, there are no clear and accepted criteria for further 
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classification. Cases such as these are generally named as DLBCL, not otherwise 
specified (NOS). Using the principles established in 1994 by the Revised European 
American Lymphoma Classification (REAL), the current organization of DLBCL was 
designed (Harris et al., 1994) and adopted in the third and fourth editions of WHO 
Classification. It was thereafter that each type of lymphoma is categorized by the 
criteria of morphology, clinical data, cytogenetics, phenotype, molecular characteristics 
and by the identification of a normal counterpart.   
 
2.1.2 Aetiology and risk factors 
 
Currently, most causes of DLBCL were remain unknown. Nevertheless, cases arising de 
novo (referred as primary) should be clearly separated from those cases manifesting 
progression or transformation (referred to as secondary) of a less aggressive lymphoma. 
These included marginal zone lymphoma or nodular lymphocyte predominant Hodgkin 
lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular 
lymphoma. Congenital and acquired immunodeficiency states as well as agents causing 
molecular abnormality are predisposing factors for DLBCL (Hartge P, 2004). 
 
 A plethora of chemical substances, which involved fertilizers and pesticides 
(Weisenburger, 1985), and medical drugs also have been proposed to be causative 
agents. Alkylating agents are one of the culprit, whereby their uses are to treat solid 
tumours and haematological cancers. Incidence of lymphomas as secondary tumours 
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significantly increases with the concurrent use of alkylating agents and ionizing 
radiation, usually involving irradiation of large volumes of spleen or bone marrow.  
 
 DLBCL is a hereditary disease. It can be inherited in patients with 
immunologic deficiency diseases, and in families of patients with immunologic 
disorders (Vianna, 1977, Swerdlow et al., 2008). The incidence rate of diffuse 
aggressive lymphomas that affecting the brain seem to be higher and it has been 
reported in chronic patient who received immunosuppressant drugs, particularly after 
organ transplants. Indeed, patients who received alemtuzumab treatment for previous, 
unrelated haematological malignancies were also detected with EBV-positive DLBCL 
and it has been reported in a few trials (Abruzzo et al., 2002, Roch et al., 2008, Sohani 
et al., 2010). In term of characteristic, secondary DLBCL has similar features to that of 
early and polymorphic cases of post-transplant lymphoproliferative disorder (PTLD), 
whereby the sustainability of the remission may depend on the reduction in 
immunosuppressive therapy alone. Nevertheless, this is different from the  therapeutic 
immunosuppression after solid organ transplantation. Prolongation of T-cell 
suppression by alemtuzumab may not result in rapid restoration of host anti-EBV and 
antitumour immunity once terminating the alemtuzumab therapy (Sohani et al., 2010). 
There is a difficulty in differentiating the influence of inheritance per se from 
immunosuppression in DLBCLs secondary to chronic iatrogenic immunosuppression. 
This may be of aetiological importance where there is no inherited background of the 
disease in the patient. Generally, Epstein-Barr virus (EBV) positivity usually manifest 
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in DLBCL emerging in the setting of one of these congenital or acquired immunologic 
disorders.  
 
 Notably, the association of DLBCL and viruses have become debatable over 
the last ten years. In fact, study has shown that there is a relationship between 
aggressive lymphomas and hepatitis-C virus (HCV) (De Vita et al., 1997) and a 
pathogenetic link has been suggested by another researcher (Luppi et al., 1998). 
Infection of HCV maybe linked to the malignant proliferation of defined B-cell subsets. 
The outcome survival of B-Non Hodgkin Lymphoma patients does not affected by 
HCV-related liver disease (De Vita et al., 1997). 
 
 Few types of lymphomas been identified to have linkage with human 
immunodeficiency virus (HIV)-infection (Cesarman, 2013). They are usually very 
aggressive and disseminated tumours occurring in an early phase of AIDS evolution. 
However, there is one malignancy that emerges in a latter phase of AIDS evolution; 
namely the primary central nervous system (PCNS) lymphoma with poor survival 
outcome. From the pathological aspects, lymphomas are divided into three categories. 
The first category involves lymphomas occurring more specifically in HIV positive 
patients (plasmablastic lymphoma (PBL) and pleural effusion lymphoma (PEL)]. The 
second group involves lymphomas occurring in other immunodeficiency states (PTLD-
like polymorphic B-cell lymphoma). The last group was lymphoid tumours occurring in 
immunocompetent patients (usually Burkitt lymphoma and DLBCL) (Rossi et al., 2010). 
The number of lymphomas’ cases among HIV positive patients have reduced 
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significantly while chemotherapy tolerability by the patients have increased with the 
initiation of the HAART therapy. 
 
 DLBCL which categorized under broad spectrum of lymphoproliferative 
disease was often associated with EBV. In regards of the two-provisional existence 
“ÉBV+DLBCL of elderly”, some of the common conditions should be taken into 
treatment consideration, for example, primary effusion lymphoma, DLBCL associated 
with chronic inflammation, monomorphic PTLD, PBL, and lymphomatoid 
granulomatosis. Monomorphic PTLD is reported in patients starting at fifth decade of 
life without any underlying immunosuppression or previously diagnosed lymphoma. 
Oyama and colleagues described it as senescence-related immune system and the 
prognosis is not as good as the age-matched EBV-DLBCL (Oyama et al., 2007).  
 
 Lymphoid proliferations often related with human herpes virus 8 (HHV8). On 
top of PEL being the prototype, Castleman disease (CD) also shown to have association 
with HHV8 (Du et al., 2001). A peculiar form of DLBCL can emerge in the context of 
the multicentric variant of the latter, which frequently related to HIV infection. 
Monoclonal proliferation of HHV8+ lymphoid cells, which resembling plasmablasts 
and expressing IgM is able to sustain the form of disease. Even though the 
nomenclature plasmablastic is used, the cancer cells correspond to naïve, IgM-
producing plasma cells without Ig somatic hypermutation. Conversely, PBL occurring 
in the oral buccal or other extranodal sites, usually indicate class-switched and 
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hypermutated Ig genes. This type of lymphoma must be differentiated from the earlier 
form as treatment may varies (Martelli et al., 2013). 
 
2.1.3 Classification   
 
DLBCL is a heterogeneous group of cancers. It contains cells with huge nuclei; usually 
bigger than those of tissue macrophages and at least double the size of a small 
lymphocyte. Involvement of extranodal sites may happen as well. Beside arising de 
novo, DLBCL may also emerge from the progression or transformation of a less 
aggressive B-cell neoplasm, such as follicular lymphoma, chronic lymphocytic 
leukemia, lymphoplasmacytic lymphoma, lymphocyte predominant Hodgkin lymphoma 
and marginal zone lymphoma. Four categories have been subdivided, some of which 
were not mentioned in previous schemes in the fourth edition of the WHO 
Classification of Haematopoietic and Lymphoid Tumours (Swerdlow et al., 2008); The 
categories including DLBCL- not otherwise specified (DLBCL, NOS), large cell 
lymphoma of terminally differentiated B-cells, DLBCL with predominant extranodal 
location and borderline cases. The organization of these neoplasms is quite complex as 
each category may further categorize according to morphology and/or clinic-pathologic 
aspects (Table 1). 
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Table 2.1: Classification of Diffuse Large B-cell lymphoma (DLBCL) 
Diffuse large B-cell lymphoma (DLBCL), NOS 
• T-cell/histiocyte rich large B-cell lymphoma (T/HRBCL) 
• EBV+ DLBCL of the elderly  
DLBCL with predominant extranodal location 
• Primary mediastinal (thymic) large B cell lymphoma (PMBL) 
• Intravascular large B-cell lymphoma (IVLBCL) 
• Primary cutaneous DLBCL, leg type (PCLBCL, leg type) 
• Primary DLBCL of CNS 
• Lymphomatoid granulomatosis 
Large-cell lymphomas of terminally differentiated B-cells 
• ALK positive large B-cell lymphoma 
• Plasmablastic lymphoma (PBL) 
• Primary effusion lymphoma (PEL) 
• DLBCL associated with chronic inflammation 
B-cell neoplasms with features intermediated between DLBCL and other lymphoid 
tumours  
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and Burkitt lymphoma  
• B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and classical Hodgkin lymphoma 
Note. Adapted from  (Martelli et al, 2013). 
 
2.1.4 Staging 
 
Reviewing the tissue biopsy is crucial in making a diagnosis of DLBCL. For DLBCL 
diagnosis, excisional biopsy is a must; whereas core needle biopsy ought to be carried 
out only when other surgical approaches permitted in the case. In a suspected 
lymphoma presentation, the tissue sample can be obtained from enlarged superficial 
lymph node or on lymphoid tissue in Waldeyer’s ring or on mediastinal adenopathy by 
core needle biopsy, mediastinoscopy or mediastinotomy (Andersson et al., 1992) or on 
retroperitoneal adenopathy by ultrasound-guided core needle biopsy, laparoscopy or 
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laparotomy (Pappa et al., 1996). After establishment of the diagnosis, the primary step 
is the evaluation before giving treatment as well as staging. 
 
 Staging system has been practiced since decades ago. Primarily, DLBCL 
staging used the standard system that was proposed at the Ann Arbor Conference in 
year 1971 (Carbone et al., 1971) and the Cotswlds modification (Lister et al., 1989). 
This staging system comprises the manifestation of B symptoms (fever > 38C for at 
least three consecutive days, night sweats, unexplained body weight loss of more than 
10% during the 6 months prior to diagnosis), the presence of extranodal disease, and  
amount of involvement sites and their relation to the diaphragm. The manifestation of B 
symptoms should be noted, and other symptoms may show specific sites of involvement.  
Besides, patients also need to be screened for their history and physical examination. A 
thorough physical examination is needed, which include assessment of all lymph node  
enlargement, recording site and size of all abnormal lymph nodes, evaluation of the 
presence of hepatosplenomegaly, inspection of the skin, detection of palpable masses, 
and inspection of Waldeyer’s ring. Assessing patient’s status with ECOG performance 
scoring is vital in all patients. This is particularly essential for the patients who 
involving in clinical trials. 
 
 The confirmatory of NHL disease required laboratory studies. NHL patients 
should be assessed for bone marrow reserves using a full blood count and a differential 
count of white blood cell. This is important as vigilant examination of the peripheral 
blood able to identify the presence of circulating lymphoma cells. Beside assessing the 
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liver and kidney function, lactate dehydrogenase (LDH) also play a pivotal role as 
parameter of tumour activity and it has been incooperated into the International 
Prognostic Index (Project, 1993). In fact, risk for urate nephropathy may be predicted 
by the urid acid level and all patients should have been assessed for their HIV, HBV, 
and HCV status as well. 
 
 Bone marrow aspirate and biopsy are compulsory assessments in confirming 
diagnosis. In order to improve 10-20% sensitivity of detection of NHL involvement, 
biopsy of the bilateral bone marrow have been suggested. Otherwise, a unilateral bone 
marrow specimen with the size of more than two centimeters is often enough. 
Additionally, MRI of the brain in patients with high risk of central nervous system 
(CNS) progression and lumbar puncture examination to assess liquor cytology 
identifying subclinical meningeal involvement maybe needed in diagnosing DLBCL.  
 
 The current standard practice for both response evaluation and staging is using 
18Fluorodeoxyglucose Positron Emission Tomography (PET). Plethora of studies 
showed that OS and PFS in aggressive lymphomas with or without residual masses 
detected with CT scan are highly predictive by the PET scan after completed the 
treatment. Besides, PET scan able to differentiate between lymphoma and necrosis or 
fibrosis in residual masses. Evaluation of combination Workshop Criteria (IWC) and 
PET was performed in a retrospective analysis of 54 patients with NHL. In the context 
of this study, new recommendations has been provided by the International 
Harmonization Project for response criteria for aggressive malignant lymphomas, 
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incorporating PET into the definition of response at the end of treatment (Juweid et al., 
2007, Seam et al., 2007). PET scan should not be used in follow-up setting as it 
increases the rate of false positives and the fact that its increased sensitivity does not 
bring clinical benefit. Further evaluations are needed to assess the benefit of using PET 
and the cost effectiveness during the follow-up phase. 
 
 Additionally,  “specific” staging studies that differ somewhat by site are needed 
especially for DLBCL developed in certain extranodal sites: this is particularly 
important in primary CNS lymphoma (Ferreri, 2013), gastric DLBCL (Ferreri and 
Montalban, 2007) and testicular DLBCL (Zucca et al., 2003).   
 
Table 2.2: Ann Arbor staging  
Stage  
I Involvement of a single lymphatic region (I) or localized 
involvement of single extralymphatic organ or site (IE) 
II Involvement of two or more lymphatic regions on the same side of 
the diaphragm (II) or localized involvement of a single 
extralymphatic organ or site and of one or more lymphatic regions 
on the same side of the diaphragm (IIE) 
III Involvement of lymphatic regions on both sides of the diaphragm 
IV Diffuse or disseminated involvement of one or more 
extralymphatic organs with or without lymphatic involvement 
Note. Adapted from  (Tilly et al., 2015). 
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2.2 Prognosis 
2.2.1 Clinical presentation and natural history 
 
A variety of clinical presentation, treatment sensitivity and behaviour can be seen with 
each DLBCL category and their morphology and/or clinic-pathology variants aspects. 
Apparently, the presentation and natural history for each DLBCL category is difficult to 
report (Martelli et al., 2013). For DLBCL-NOS, it can be seen in adult patients, with a 
median age of 70 years old as well as in children (Swerdlow et al., 2008). Extranodal 
site plays an important part in determining the variable of clinical presentation, 
prognosis and behaviour of DLBCL-NOS (Moller et al., 2004). In general, patients 
rapidly manifest enlarging and usually have no symptomatic mass either at a single 
nodal or extranodal site. With regard to an extranodal organ, this presentation may 
account up to 40% of the patients (Moller et al., 2004). About 20% of patients who have 
these malignancies occur in localized manner and rarely disseminated, while 33% of 
patients manifested systemic symptoms. Overall, although DLBCL is an aggressive 
malignancy, yet it is potentially curable (Armitage, 1997). Patients with limited disease 
have a high cure rate of a 5-year progression free survival (PFS) ranging from 80% to 
85%. On the other hand, patients with stage III/IV disease or symptomatic disease have 
a 5-year PFS of approximately 50% (Martelli et al., 2013).    
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2.2.2 Prognostic Factors 
 
Prognostication of DLBCL can be categorized into those related primarily to the disease 
itself (eg. stage, tumour burden, proliferating fraction, extranodal involvement), the 
patient (eg. age and performance status), those related to aggressiveness indicators (eg. 
LDH serum level, β2-microglobulin levels, proliferating fraction), and those related to 
the treatment option. Nevertheless, involvement of extranodal sites may require special 
treatment options. These include the brain (Ferreri, 2011) or testis (Zucca et al., 2003), 
which constitute certain entities associated with poor prognosis. Besides, patient’s 
outcome is highly predictive by response rate after initiation of primary treatment.  
 
 Based on clinical factors from more than 4000 patients, the International 
Prognostic Index (IPI) and age-adjusted International Prognostic Index (aaIPI) have 
been created as models for predicting outcomes of the disease (Project, 1993). In term 
of accuracy in predicting survival, IPI or aaIPI models have proven to be superior than 
the Ann Arbor classification. The aaIPI scoring which includes indicators such as LDH, 
performance status and stage, is the most commonly used in clinical practice and it is 
helpful in stratifying patients regardless of age. In fact, after the rituximab era, a revised 
version has been created (R-IPI) (Sehn et al., 2007). Nonetheless, in rituximab era, the 
IPI still remain the only benchmark of DLBCL prognosis although it has been 
documented to be robust in different series of DLBCL (Ziepert et al., 2010). 
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 A plethora of prognostic factors for DLBCL have been identified; mainly 
biological parameters that is tumour related and indirectly to the host. This creates room 
for improvement in term of designing new therapeutic options as well as knowing more 
about the disease. Nevertheless, treatment decisions using these factors still remain 
investigational. Interestingly, biological heterogeneity in DLBCL can be obtained from 
the GEP of the malignant cells and their surroundings. In fact, some studies identified 
certain distinct subsets, including activated B-cell-like (ABC) and germinal-centre-like 
(GC) DLBCL to have different activation pathways, genetic markers, and clinical 
outcomes (Alizadeh et al., 2000, Shipp et al., 2002, Lenz  et al., 2008). The BCL-6, 
MUM1 immunohistochemistry and CD10, have the same predictive abilities that enable 
them to be potential assistance for the gene expression profiles (Hans et al., 2004). At 
present, more data is needed for the practice of GEP or immunohistochemistry in the 
clinical settings. Nevertheless, some preliminary data from Dunleavy suggested that 
certain drugs are found to be more active in one of the GEP subgroups of recurrent 
DLBCL compared to the other (Dunleavy et al., 2009). A recent retrospective study also 
showed that ABC-DLBCL patients with respect to GCB-cell-DLBCL receiving 
lenalidomide as salvage therapy were significantly showed better response rate 
(Hernandez-Ilizaliturri et al., 2011). However, larger prospective type of studies are 
needed to confirm the prognostic value of these markers.  
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2.3 Chemotherapy 
 
Chemotherapy has a pivotal role in cancer treatment whereby the standardized 
chemotherapeutic regimen uses anti-cancer drugs whether as monotherapy or 
combination therapy. The purpose of chemotherapy given is to cure the disease, or 
perhaps to reduce symptomatology (palliative chemotherapy) or to prolong life. Based 
on the cytotoxicity properties, chemotherapeutic agents able to interrupt cell division 
(mitosis) but the susceptibility of cancer cells to these agents are variable (Kehe et al., 
2009, Malhotra and Perry, 2003). To some extent, chemotherapy can be treat as an 
option to pose stress to cells or terminate them, which may then lead to cell death or 
apoptosis (Makin and Hickman, 2000).  
 
 Normal cells are rapidly dividing and are thus sensitive to anti-mitotic drugs 
which may subsequently damage by the chemotherapy. These include those cells in the 
hair follicles, bone marrow and digestive tract. As a result, some of the commonly 
reported side-effects of chemotherapy including alopecia (hair loss), myelosuppression 
(decreased production of blood cells, hence also immunosuppression), and mucositis 
(inflammation of the lining of the digestive tract) (Rajesh K. Saini, 2012). Nevertheless, 
these side effects are temporary and do not prolong after chemotherapy. Chemotherapy 
drugs have some effect on immune cells (especially lymphocytes). This enable 
chemotherapy drugs to be used in a host of diseases that result from harmful over 
activity of the immune system against self or termed as autoimmunity. The autoimmune 
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diseases may include multiple sclerosis, systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA), vasculitis and many others (Zack, 2012).  
 
2.3.1 Cyclophosphamide 
 
Cyclophosphamide is used as a chemotherapeutic agent besides suppressing the 
immune system. In the field of hematology, it is used to treat lymphoma, leukemia 
multiple myeloma. Meanwhile in oncology, solid tumours such as breast cancer, 
sarcoma, ovarian cancer, and small cell lung cancer can be treated by 
cyclophosphamide. Besides, cyclophosphamide also has a role in nephrotic syndrome 
and following organ transplant due to its immunosuppressive effect. Cyclophosphamide 
can be taken intravenously or even enterally . Majority people experience some sort of 
side effects from the used of cyclophosphamide. Common side effects of 
cyclophosphamide include loss of appetite, low white blood cell counts, hair loss, 
vomiting and bleeding from the bladder. Severe side effects were also documented 
which include pulmonary fibrosis, fertility problems, allergic reactions and increased 
future risk of cancer. Cyclophosphamide originated from two groups of drugs, mainly 
alkylating agent and nitrogen mustard. The mechanism of action involves interfering 
with the replication of DNA and the development of RNA (McEvoy, 2004 ). 
 
 Absorption of oral cyclophosphamide is fast which then converted to active 
metabolites in the liver. This process is catalyzed by mixed-function oxidase enzymes 
(cytochrome P450 system) (Cohen and Jao, 1970, Huttunen et al., 2011) where the main 
